Analysts Offer Insights on Healthcare Companies: Achieve Life Sciences (ACHV) and Roivant Sciences (ROIV)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Achieve Life Sciences (ACHV – Research Report) and Roivant Sciences (ROIV – Research Report) with bullish sentiments.

Claim 50% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Achieve Life Sciences (ACHV)

H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating on Achieve Life Sciences today and set a price target of $12.00. The company’s shares closed last Friday at $4.12.

According to TipRanks.com, Folkes is a 3-star analyst with an average return of 1.9% and a 41.9% success rate. Folkes covers the Healthcare sector, focusing on stocks such as Sagimet Biosciences, Inc. Class A, Connect Biopharma Holdings, and Rani Therapeutics Holdings. ;'>

Currently, the analyst consensus on Achieve Life Sciences is a Strong Buy with an average price target of $14.40.

See today’s best-performing stocks on TipRanks >>

Roivant Sciences (ROIV)

H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Roivant Sciences today and set a price target of $26.00. The company’s shares closed last Friday at $25.02.

According to TipRanks.com, Tsao is a 5-star analyst with an average return of 18.6% and a 53.2% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Neumora Therapeutics, Inc., and Rapport Therapeutics, Inc. ;'>

Roivant Sciences has an analyst consensus of Strong Buy, with a price target consensus of $27.63.

Disclaimer & DisclosureReport an Issue